P537: Anemia in Crohn's Disease: Response to treatment and risk of recurrenceECCO'21 VirtualYear: 2021
Authors: Gharbi, G.(1);Bibani, N.(1);Sabbah, M.(1);Nawel, B.(1);Trad, D.(1);Ouakaa, A.(1);Elloumi, H.(1);Gargouri, D.(1);
(1)Habib Thameur Hospital, Gastroenterology, tunis, Tunisia
P538: The reliability of patient performed fecal calprotectin testingECCO'21 VirtualYear: 2021
Authors: Crouwel, F.(1);Dijkhuis, L.E.J.L.(1);Duijvestein, M.(1);Buiter, H.J.C.(2);De Boer, N.K.(1);Hamer, H.M.(3);
(1)Amsterdam UMC- location VUmc, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC- location VUmc, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands;(3)Amsterdam UMC- location VUmc, Department of Clinical Chemistry, Amsterdam, The Netherlands
P539: Unmet needs in advanced therapy-naïve (ATN) and advanced therapy-experienced (ATE) moderate-to-severe (mod-sev) ulcerative colitis (UC) patients in the United States (US)ECCO'21 VirtualYear: 2021
Authors: Afzali, A.(1);Kakehi, S.(2);Lapensee, K.(2);Lukanova, R.(3);Hennessy, F.(3);Knight, H.(3);Singh, K.(2);
(1)The Ohio State University Wexner Medical Center, Gastroenterology, Columbus, United States;(2)Bristol Myers Squibb, Health Economics and Outcomes Research, Princeton, United States;(3)Adelphi Real World, Gastroenterology, Bollington, United Kingdom
P540: Real-world evidence on treatment switching in patients with moderate-to-severe ulcerative colitis: a systematic review of literatureECCO'21 VirtualYear: 2021
Authors: Singh, H.(1);Wilson, L.(2);Pandey, A.(3);Tencer, T.(4);Kumar, J.(4);
(1)Amaris Consulting Ltd, Health Economics & Market Access HEMA, Toronto, Canada;(2)Amaris Consulting Ltd, Health Economics & Market Access HEMA, Shanghai, China;(3)Amaris Consulting Ltd, Health Economics & Market Access HEMA, London, United Kingdom;(4)Bristol Myers Squibb, Global HEOR, Princeton, United States
P541: Efficacy, efficiency and aceptability of telemedicine for inflammatory bowel disease patients follow-up care during the COVID-19 pandemic lockdown.ECCO'21 VirtualYear: 2021
Authors: Ramos Lopez, L.(1);Reygosa, C.(1);Carrillo-Palau, M.(1);Alonso-Abreu, I.(1);González, Y.(1);de la Barreda, R.(1);Amaral , C.(1);Hernández, A.(1);Benítez-Zafra, F.(1);Hernández-Guerra, M.(1);
(1)Hospital Universitario De Canarias, Department of Gastroenterology, Santa Cruz De Tenerife, Spain
P543: The role of social support on psychological distress and health-related quality of life in adults with mild to moderately active Crohn's disease.ECCO'21 VirtualYear: 2021
Authors: Regev, S.(1);Goren, G.(1);Schwartz, D.(2);Sergienko , R.(3);Friger, M.(4);Nemirovsky , A.(5);Greenberg, D.(6);Monsonego, A.(7);Sarid, O.(1);Slonim-Nevo, V.(1);Odes, S..(8);
(1)Ben-Gurion University of the Negev- Beer Sheva- Israel, Spitzer Department of Social Work, Beer Sheva, Israel;(2)Faculty of Health Sciences- Ben-Gurion University of the Negev- and Soroka Medical Center -Beer-Sheva- Israel, Department of Gastroenterology and Hepatology, Beer Sheva, Israel;(3)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, Department. of Public Health, Beer Sheva, Israel;(4)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, Department of Public Health, Beer Sheva, Israel;(5)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, The Shraga Segal Department of Microbiology- Immunology- and Genetics, Beer Sheva, Israel;(6)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, Department of Health Systems Management- School of Public Health- Guilford Glazer Faculty of Business and Management, Beer Sheva, Israel;(7)Ben-Gurion University of the Negev- Beer-Sheva- Israel, The Shraga Segal Department of Microbiology- Immunology- and Genetics- Faculty of Health Sciences- and The National Institute of Biotechnology in the Negev, Beer Sheva, Israel;(8)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, Department of Gastroenterology and Hepatology, Beer Sheva, Israel
P544: Point-of-care finger prick test for C-reactive protein, infliximab and adalimumab serum concentrationsECCO'21 VirtualYear: 2021
Authors: Volkers, A.(1);Löwenberg, M.(1);Bray, K.(2);Bahur, B.(2);Braad, M.(1);Abeling, Y.(1);Gecse, K.(1);Duijvestein, M.(1);Ponsioen, C.(1);D'Haens, G.(1);
(1)AmsterdamUMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)ProciseDx, Clinical Dev & Medical Affairs, San Diego, United States
P545: Calprotectin at week 12 is a predictor for histological remission in ulcerative colitis patients treated with VedolizumabECCO'21 VirtualYear: 2021
Authors: Rubstov, D.(1);Kakkadasam Ramaswamy, P.(1);Edwards, J.(1);Shukla, D.(1);Willmann, L.(1);Moattar, H.(1);Bhullar, M.(1);Ishaq, N.(1);Dorrington, A.(1);Mohsen, W.(1);
(1)Gold Coast University Hospital, Department of Digestive Health, Southport, Australia
P547: Safety and efficacy of vedolizumab in the treatment of patients with moderate to severe Ulcerative Colitis: a systematic review and meta-analysisECCO'21 VirtualYear: 2021
Authors: KhorshidFASGE, M.(1);Alboraie, M.(2);Abbas, W.(3);Sayed, Z.E.(3);El-Nady, M.(4);
(1)EDGE Foundation, Department of Clinical Research, Cairo, Egypt;(2)Al-Azhar University, Department of Internal Medicine, Cairo, Egypt;(3)Assiut University, Department of Internal Medicine, Assiut, Egypt;(4)Cairo University, Department of Internal Medicine, Cairo, Egypt
P548: Drug Survival in Patients with Inflammatory Bowel disease: An observational studyECCO'21 VirtualYear: 2021
Authors: Kubesch, A.(1);Grimm, L.(1);Stratmann, K.(1);Knabe, M.(1);Filmann, N.(2);Sprinzl, K.(1);Hausmann, J.(1);Blumenstein, I.(1);
(1)Goethe-University Hospital, Department of Internal Medicine 1, Frankfurt, Germany;(2)Goethe-University Hospital, Institute of Biostatistics and Mathematical Modeling, Frankfurt, Germany
P549: Changing Lanes: Switching Therapies in Inflammatory Bowel Disease, An Observational Study.ECCO'21 VirtualYear: 2021
Authors: Mc Gettigan, N.(1);Leung, E.(2);Harhen, A.(2);Anderson, E.(2);McMahon, S.(2);Walshe, M.(2);Keohane, J.(2);Sengupta, S.(2);
(1)Our Lady of Lourdes Hospital- Drogheda, Gastroenterology, Galway, Ireland;(2)OLOL Drogheda, Gastroenterology, Drogheda, Ireland
P550: Short term effects of a combined lifestyle intervention in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Lamers, C.R.(1,2);de Roos, N.M.(2);Heerink, H.H.(3);van de Worp - Kalter, L.A.(4);Witteman, B.J.M.(1,2);
(1)Hospital Gelderse Vallei, Gastroenterology and Hepatology, Ede, The Netherlands;(2)Wageningen University & Research, Human Nutrition and Health, Wageningen, The Netherlands;(3)Hospital Gelderse Vallei, Dietetics, Ede, The Netherlands;(4)Hospital Gelderse Vallei, Physical Therapy, Ede, The Netherlands
P551: Lack of adherence to infliximab in inflammatory bowel disease patients contributes to loss of response in Crohn’s disease.ECCO'21 VirtualYear: 2021
Authors: Ferreiro Iglesias, R.(1);Gonzalez-Lopez, J.(2);Calvino-Suarez, C.(1);Mauriz-Barreiro, V.(1);Baston-Rey, I.(1);Cruz, R.(3);Dominguez-Munoz, J.E.(1);Barreiro-de Acosta, M.(1);
(1)University Hospital Santiago De Compostela CHUS, Department of Gastroenterology- IBD Unit, Santiago De Compostela, Spain;(2)University Hospital Santiago De Compostela CHUS, Department of Pharmacy, Santiago De Compostela, Spain;(3)Universidad de Santiago de Compostela, Grupo de Medicina Genómica, Santiago de Compostela, Spain
P552: Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.ECCO'21 VirtualYear: 2021
Authors: Xiao, Y.(1);AL Khoury, A.(2);Golovics, P.(3);Kohen, R.(2);Afif, W.(2);Wild, G.(2);Friedman, G.(4);Galiatsatos, P.(4);Hilzenrat, N.(4);Szilagyi, A.(4);Wyse, J.(4);Cohen, A.(4);Bitton, A.(4);Bessissow, T.(4);Lakatos, P.L.(2);
(1)McGill University, Department of Medicine- Internal Medicine, Montreal H3H1E1, Canada;(2)McGill University, Department of Medicine- Gastroenterology, Montreal H3H1E1, Canada;(3)HDF Medical Center, Division of Gastroenterology, Budapest, Hungary;(4)Jewish General Hospital, Department of Medicine- Gastroenterology, Montreal H3H1E1, Canada
P553: Factors related to steroid consumption in IBD patients: Evidence from a multicenter StudyECCO'21 VirtualYear: 2021
Authors: Barkan, R.(1); Shpoker , L.(2);Abboud, R.(2);Nafrin, S.(3);Ganon , M.(4);Ilsar , T.(4);Volf , T.(5);Markovitch , L.(6);Saban , M.(7);Kagan, I.(8);
(1)Rabin Medical Center - Beilinson Hospital, IBD Center- Division of Gastroenterology, Petah Tikva, Israel;(2)Bny Zion- Medical Center, IBD Center- Division of Gastroenterology, Haifa, Israel;(3)Hillel Yaffe Medical Center, . IBD Center- Division of Gastroenterology, - Hadera, Israel;(4)Hadassah Ein Kerem Medical Center, IBD Center- Division of Gastroenterology, Jerusalem, Israel;(5)Shamir Medical Center, IBD Center- Division of Gastroenterology, Tzrifin, Israel;(6)Rabin Medical Center - Hasharon Hospital, IBD Center- Division of Gastroenterology, Petah Tikva, Israel;(7)Gertner institute, for epidemiology and health policy research, Ramat-Gan, Israel;(8)School of Health Professions- Sackler Faculty of Medicine- Tel Aviv University, Nursing Department-, Tel Aviv, Israel
P554: Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?ECCO'21 VirtualYear: 2021
Authors: SinaDr., M.(1);Pemaj, X.(1);Akshija, I.(2);Hysa, A.(1);Koçollari, A.(1);Prifti, S.(1);
(1)University Hospital Center Mother Theresa, Internal Medicine/ Gastroenterology, Tirana, Albania;(2)University Hospital Center Mother Theresa, Statistics, Tirana, Albania
P555: Outcomes of multiswitching from original infliximab to biosimilars in patients with inflammatory bowel diseaseECCO'21 VirtualYear: 2021
Authors: Nascimento, C.(1);Revés, J.(1);Morão, B.(1);Frias Gomes, C.(1);Gouveia, C.(1);Palmela, C.(1);Roque Ramos, L.(1);Fidalgo, C.(1);Cravo, M.(1);Glória, L.(1);Torres, J.(1);
(1)Hospital Beatriz Ângelo, Gastrenterology, Loures, Portugal
